Filing summary
Filing identity and period: The supplied document is Caladrius Biosciences, Inc.’s Form 10-K for the fiscal year ended December 31, 2017, filed March 22, 2018. It does not match the request metadata identifying Lisata Therapeutics, Inc. and “2016 Q4.” The figures below summarize the supplied filing, not a Lisata filing or a standalone fourth quarter.
Business context
Caladrius develops cellular therapies and had no approved products or product-sales revenue. Its lead program was CLBS03, a Phase 2 autologous regulatory T-cell therapy for recent-onset type 1 diabetes. Its CD34-cell programs included CLBS12 for critical limb ischemia in Japan and a planned study for coronary microvascular dysfunction. The company sold its remaining 80.1% interest in PCT to Hitachi in May 2017; PCT is presented as discontinued operations.
Financial performance and liquidity
- Continuing operations: Operating expenses were $27.6 million, down 6% from $29.5 million in 2016. R&D was $15.8 million versus $16.7 million; G&A was $11.8 million versus $12.8 million. Continuing-operations net loss attributable to common shareholders was $16.0 million, compared with $31.0 million in 2016.
- Reported net result: Net income attributable to common shareholders was $23.0 million, versus a $32.7 million loss in 2016. The 2017 result included $39.0 million of discontinued-operations income attributable to common shareholders, driven principally by the $51.7 million gain on the PCT sale. This was not recurring operating profit.
- Revenue: The filing reports no product-sales revenue from continuing operations. PCT, classified as discontinued operations, reported $16.0 million revenue through its sale in 2017, compared with $42.0 million for 2016.
- Cash flow: Continuing operations used $20.2 million of operating cash in 2017, versus $28.2 million in 2016. Continuing investing activities provided $41.5 million, primarily reflecting net PCT-sale proceeds; continuing financing activities used $0.9 million.
- Liquidity: At year-end, cash and cash equivalents were $29.2 million, restricted cash $5.0 million, and marketable securities $25.9 million—about $60.1 million combined. Working capital was $51.8 million; stockholders’ equity was $50.5 million.
- Debt: The $5.7 million Oxford Finance loan was fully repaid in May 2017. Year-end notes payable were approximately $0.2 million; no long-term debt remained.
Material changes, outlook, and risks
- The PCT divestiture was a major strategic and reporting change. Consideration included $75.0 million cash plus a $4.4 million adjustment. A further $5.0 million milestone payment depends on PCT reaching a revenue target for 2017–2018; its year-end fair value was recorded as zero. A $5.0 million escrow balance remained restricted, subject to indemnification claims.
- Management said available cash was expected to fund CLBS03 development and other expenses for at least 12 months following issuance of the financial statements. It also stated that substantial additional capital would be needed over time and that financing may not be available on acceptable terms.
- A February 2018 at-the-market agreement permits sales of up to $12 million of common stock, at management’s discretion, with a 3% sales commission; sales could dilute existing shareholders.
- CLBS03 enrollment was completed at 110 patients in January 2018. The filing reports that a subsequent interim analysis, publicly released in March 2018, found the therapy well tolerated and non-futile; this is not a final efficacy result. CLBS12 enrollment opened in Japan in December 2017, and management described conditional approval as a possibility dependent on trial results and regulatory review.
- Key risks include continuing losses and cash burn, dependence on future financing or partners, clinical and regulatory uncertainty, trial enrollment and manufacturing constraints, reliance on external manufacturers, and potential dilution. The company reported effective disclosure controls and internal control over financial reporting; the auditor issued an unqualified opinion on the financial statements but did not audit internal-control effectiveness.
Important facts for investors to verify
- Confirm the issuer and period: the document is Caladrius Biosciences’ 2017 Form 10-K, not a Lisata Therapeutics 2016 filing.
- Separate the $23.0 million reported net income from the $16.0 million continuing-operations loss and assess the nonrecurring PCT-sale gain.
- Track cash burn against the stated 12-month runway, subsequent financing, and any use of the $12 million ATM facility.
- Check the final disposition of the $5.0 million escrow, any indemnification claims, and whether the contingent PCT milestone is achieved.
- Review full CLBS03 trial results and subsequent regulatory and funding developments; interim non-futility is not proof of efficacy or approval.